RxDoctor Payments Data

Andrew Parker, MD

Allergy & Immunology · Portland, MENPI 1902168107

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,325 of the $6,394 with a category attached, or 67.6%. Aimmune Therapeutics, Inc. accounts for 71.9% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2020 at $4,607 and has fallen 77.3% since, to $1,046 in 2025.

$6,394in general payments, 2019–2025

Across 73 payments — averaging $87.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aimmune Therapeutics, Inc.$5K
  • Regeneron Healthcare Solutions, Inc.$388
  • Teva Pharmaceuticals USA, Inc.$229
  • Optinose US, Inc.$192
  • Sanofi$166
  • AstraZeneca$147
  • plus $677 from 14 others

What the payments were for

  • Consulting fees$4,32568%
  • Travel & lodging$2294%
  • Food & beverage$1,80728%
  • Education$321%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy & immunology providers in Maineto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$77,667
Medicare patients
175
Services billed
3,749

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab26$69,550
NucalaMepolizumab11$38,853
Spiriva RespimatTiotropium Bromide25$14,677
Epinephrine26$5,929
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$2,827
Azelastine Hcl53$1,090
Ipratropium Bromide23$722
Montelukast Sodium41$680
Albuterol Sulfate HfaAlbuterol Sulfate17$505
Fluticasone Propionate23$466

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKNucala$14$38,85311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy & immunology providers in Maineon file to place this against a meaningful peer group, so we don't.

Other allergy & immunology in Portland

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →